Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 6/20 | 0.54 |
| ▸ | SSTR1 | P30872 | 6/20 | 0.49 |
| ▸ | SSTR2 | P30874 | 6/20 | 0.49 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.49 |
| ▸ | SSTR3 | P32745 | 6/20 | 0.49 |
| ▸ | SSTR5 | P35346 | 6/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.42 |
| ▸ | CDC25B | P30305 | 5/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22168466 | 0.89 | SELP (0.51) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL19400449 | 0.89 | SELP (0.51) | SELPPTPN1CDC25BTACR1PTPN2 | |
| SCHEMBL22168454 | 0.89 | SELP (0.51) | SELPPTPN1CDC25BTACR1PTPN2 | |
| SCHEMBL22168473 | 0.89 | SELP (0.51) | SELPPTPN1CDC25BTACR1PTPN2 | |
| SCHEMBL22168448 | 0.89 | SELP (0.51) | SELPPTPN1CDC25BTACR1PTPN2 | |
| SCHEMBL22168450 | 0.89 | SELP (0.51) | SELPPTPN1CDC25BTACR1PTPN2 | |
| SCHEMBL22168453 | 0.89 | SELP (0.51) | SELPPTPN1CDC25BTACR1PTPN2 | |
| SCHEMBL22168508 | 0.89 | SELP (0.52) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL22168487 | 0.88 | SELP (0.52) | SELPPTPN1CDC25BTACR1PTPN2 | |
| SCHEMBL22168463 | 0.88 | SELP (0.52) | SELPPTPN1CDC25BTACR1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919926-B2 | Compound or salt thereof, natural killer T cell activator, and pharmaceutical composition | KEIO UNIVERSITY (JP) | 2021-02-16 | — | — | US | disclosed |
| US-20200207798-A1 | COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR, AND PHARMACEUTICAL COMPOSITION | KEIO UNIVERSITY (JP) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207798-A1 | COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR, AND PHARMACEUTICAL COMPOSITION | CD4, NFATC1, PBK | SELP 776/4885SSTR1 839/4885SSTR2 1985/4885 |
| US-10919926-B2 | Compound or salt thereof, natural killer T cell activator, and pharmaceutical composition | CD4, NFATC1, PBK | SELP 758/4885SSTR1 598/4885SSTR2 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.